Rinvoq (Upadacitinib)
- Medicine Name: Rinvoq
- Generic Name: Upadacitinib
- Dosage Form & Strength: Tablets: 15 mg, 30 mg, and 45 mg
- Manufactured By: AbbVie Inc.
Rinvoq is a Janus kinase (JAK) inhibitor used for the treatment of:
Rheumatoid Arthritis (RA): Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to single or multiple TNF blockers.
Limitations of Use: Use of rinvoq tablets along with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants (azathioprine, cyclosporine) is not recommended.
Psoriatic Arthritis: Adults with active psoriatic arthritis who have had an inadequate response or intolerance to single or multiple TNF blockers.
Limitations of Use: Use of Rinvoq along with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants (azathioprine, cyclosporine) is not recommended.
Atopic Dermatitis: Adults and pediatric patients aged 12 years and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other existing systemic medicines, including biologics, or when use of those therapies are inadvisable.
Limitations of Use: Rinvoq is not recommended for use along with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Ulcerative Colitis: Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to single or multiple TNF blockers.
Limitations of Use: Use of Upadacitinib tablets along with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants (azathioprine, cyclosporine) is not recommended.
Ankylosing Spondylitis: Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to single or multiple TNF blockers.
Limitations of Use: Use of Rinvoq along with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants (azathioprine, cyclosporine) is not recommended.
Recommended Dosage: The recommended dosage of Rinvoq tablets should be taken orally with or without food. Tablets should be swallowed whole. It should not be split, crushed, or chewed.
Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis:
- The recommended dosage of Rinvoq is 15 mg once daily.
Atopic Dermatitis:
- Pediatric Patients aged 12 Years and Older Weighing at Least 40 kg and Adults Less Than 65 Years of Age: Start treatment with 15 mg once daily. In case an adequate response is not achieved, consider increasing the dosage to 30 mg once daily. Discontinue therapy in case an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose required to maintain response.
- Adults 65 Years of Age and Older: The recommended dosage is 15 mg once daily.
Ulcerative Colitis:
- Adult Patients: Induction: The recommended induction dose is 45 mg once daily for 8 weeks.
- Adult Patients: Maintenance; The recommended dose for maintenance treatment is 15 mg once daily. A dose of 30 mg once a day can be used for patients with refractory, severe or extensive disease. Discontinue therapy if an adequate therapeutic response is not achieved with the 30 mg dosage. Use the lowest effective dosage required to maintain response.
- Before treatment, update immunizations and consider assessing for active and latent tuberculosis, hepatic function, viral hepatitis, and pregnancy status.
- Avoid initiation or interrupt rinvoq 45 mg tablets or any other dosage if absolute lymphocyte count is below 500 cells/mm3, absolute neutrophil count is below 1000 cells/mm3, or hemoglobin level is below 8 g/dL.
- Severe and sometimes fatal infections have been reported in patients taking Upadacitinib. Closely monitor patients for the development of signs/symptoms of infection during and after treatment with Upadacitinib. Interrupt therapy if a patient develops a severe or opportunistic infection.
- Thrombosis, including DVT, pulmonary embolism (PE), and arterial thrombosis, have emerged in patients treated for inflammatory conditions with JAK inhibitors, including rinvoq 30 mg tablets. If symptoms of thrombosis appear, patients should discontinue therapy and be evaluated promptly and treated accordingly. Avoid this medicine in patients that may be at higher risk of thrombosis.
- NMSCs may occur in patients treated with Upadacitinib. Periodic skin examination is needed for patients who are at higher risk for skin cancer. Exposure to sunlight/UV light should be limited by wearing protective clothing and considering a broad-spectrum sunscreen.
- Gastrointestinal perforations may occur with upadacitinib 15 mg tablets or with any other dosage strength. Monitor patients who may be at risk for gastrointestinal perforation (e.g., patients with a previous history of diverticulitis or taking NSAIDs). Assess promptly patients presenting with new onset abdominal pain for early identification of gastrointestinal perforation.
What documents are required to import RINVOQ to India?
RINVOQ (upadacitinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by Indian Government)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is RINVOQ available in India?
RINVOQ (upadacitinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability of Rinvoq in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
RINVOQ can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of RINVOQ (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for upadacitinib (Rinvoq) price in india.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the RINVOQ (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
- Rinvoq 15 mg
- Rinvoq 30 mg
- Rinvoq 45 mg
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.